TrialThe Lancet. Oncology2017

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Robert L Coleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.